The Present and FutureState-of-the-Art ReviewManagement of Pulmonary Arterial Hypertension
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. McLaughlin has been a consultant for Actelion Bayer, Gilead, and United Therapeutics; has received research funding for clinical trials to the University of Michigan from Actelion, Bayer, Gilead, and the National Institutes of Health (R24 HL123767); and has a relationship with United Therapeutics. Dr. Shah has received research grant support from the National Institutes of Health (R01 HL107577) and Actelion Pharmaceuticals; has received generous funding from Jo Anne and Stephen A. Schiller in support of pulmonary hypertension research; has received consulting fees from the American Board of Internal Medicine, Novartis, Bayer, DC Devices, AstraZeneca, and Alnylam Pharmaceuticals; and has received speaker fees from the Pulmonary Hypertension Association and the American Society of Echocardiography. Dr. Souza has received lecture fees from Actelion, Bayer, GlaxoSmithKline, and Bristol-Myers Squibb; and has received advisory board fees from Actelion and Bayer. Dr. Humbert has served as a consultant for Actelion, Bayer, GlaxoSmithKline, and Pfizer.